Top Markets
#1 Purr Purr +58.55%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +46.97%
#4 Kinetiq Kinetiq +31.73%
#5 Non-Playable Coin Non-Playable Coin +25.94%
#6 ApeX ApeX +25.53%
#7 Pudgy Penguins Pudgy Penguins +21.06%
#8 Morpho Morpho +19.65%
#9 Grass Grass +19.53%
#10 OriginTrail OriginTrail +19.49%
Coin of the day
Purr Purr
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Classement en actions #21166
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Prix de l'action
$4.83
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$113.30M
Changement (1 jour)
-0.62%
Changement (1 an)
-29.59%
Pays
US
Échange Coya Therapeutics, Inc. (COYA)

Catégorie

Healthcare
Ratio P/B pour Coya Therapeutics, Inc. (COYA)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Coya Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Coya Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH